SITE006-0024

SITE006 (GBR) › SITE006-0024

SITE006-0024

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2025-09-26

completed

AEs

7

Serious

3

Dropout signal

–

Adverse events

7

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-15 (study day 79); relationship: not assessed

mild assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 60); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-22 (study day 55); relationship: RELATED; serious criteria: hospitalization

severe serious assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 44); relationship: not assessed

moderate assessed

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-05-07 (study day 40); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-05-01 (study day 34); relationship: NOT RELATED

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-03-31 (study day 3); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.